Alteogen Inc

Alteogen Inc maintains a strong liquidity position, with a current ratio of 2.01 and free cash flow of 117,245,087,620 KRW, indicating the company's ability to meet short-term obligations and fund operations without external financing. However, the company's net cash position is negative after subtracting total debt, which introduces a medium liquidity risk. The debt-to-equity ratio of 0.23 suggests a conservative capital structure, with long-term debt at 100,798,982,310 KRW and total equity at 445,194,059,010 KRW.

The company's profitability is robust, with a return on equity (ROE) of 31.82% and a return on assets (ROA) of 20.27%, both significantly above the industry median for biotechnology firms. Operating income of 137,325,388,120 KRW and net income of 141,666,024,710 KRW reflect strong operational efficiency and cost control. Gross profit of 165,625,058,900 KRW on revenue of 215,858,918,960 KRW indicates a healthy gross margin, supporting the company's competitive positioning in the biosimilars market.

Geographically, Alteogen Inc's revenue is concentrated in South Korea, with no disclosed international segments in the latest financial data. The company's product portfolio is centered on biosimilars and biologics, with no material diversification across therapeutic areas or customer bases. This concentration may expose the company to regulatory and market risks specific to the South Korean healthcare sector.

The company's growth trajectory is positive, with revenue of 215,858,918,960 KRW in the latest period. Analysts project a mean price target of 437,500 KRW per share, with a median of 460,000 KRW, suggesting a consensus for continued value creation. The mean recommendation of 2.00 (on a 1-5 scale) indicates a generally positive outlook, with two strong-buy and three buy ratings. However, the absence of hold or sell ratings suggests limited downside risk in the near term.

Risk factors include the company's reliance on a narrow product portfolio and geographic exposure, which could limit resilience in the face of regulatory changes or market saturation. The risk assessment indicates a low dilution potential, with shares outstanding at 53,482,080 for both basic and diluted shares, and no recent evidence of share issuance or shelf registration. Adjustments to valuation metrics have not been applied, suggesting a clean capital structure and no material off-balance-sheet liabilities.

Recent events include the continued expansion of the company's biosimilar pipeline and the maintenance of a strong balance sheet. No material adverse events or regulatory actions have been disclosed in the latest financial filings, and the company's capital expenditure of -33,417,380,510 KRW indicates a focus on cash preservation and operational efficiency.